A Prospective, Open-Label, Multi-Center, Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) 20-70mg in Children Aged 6-12 Diagnosed With ADHD
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007901/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Assess the efficacy & tolerability of Vyvanse when children aged 6-12 years diagnosed with
ADHD are dosed to optimal effect.
提供机构：
Vivli
创建时间：
2022-06-14
